Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Some Inclusion Bodies Protect Cells from Damage by Toxic Misfolded Proteins

By LabMedica International staff writers
Posted on 20 Dec 2012
Researchers studying neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease reported in a recent paper that inclusion bodies, i.e., sites of accumulation of toxic misfolded proteins, which have traditionally been thought to accompany onset of this type of disease, actually have a cell-biological function that is not necessarily related to the disease conditions.

Investigators at the Hebrew University of Jerusalem (Israel) have been studying for several years the JUNQ (juxtanuclear quality control compartment), a novel organellar structure, which serves as a cellular processing center for misfolded and aggregated proteins. More...
JUNQ was shown to be important in managing cellular protein folding quality control, the cellular response to protein aggregation, the formation of prions, and in protecting cells from the toxic effect of aggregation.

In the current paper, which was published in the September 25, 2012, issue of the journal Proceedings of the National Academy of Sciences of the United States of America, the investigators elaborated on the function of JUNQ by presenting direct evidence of a quality control function for JUNQ inclusions in human cultured cells. JUNQ compartments concentrated soluble misfolded proteins together with chaperones and proteasomes, and facilitated their degradation.

The data further showed that the accumulation of insoluble aggregates in the JUNQ inhibited the degradation of other misfolded proteins by sequestering the essential chaperone Hsp70 (heat shock protein 70) and thereby blocking the path of quality control substrates to the proteasome. Rerouting toxic aggregates from the JUNQ to an insoluble polyQ inclusion restored the JUNQ protein degradation function and rescued cell viability.

The authors concluded that toxic and nontoxic inclusions represented different sites of aggregate deposition, with different cell biological properties. They proposed a new approach to treating neurodegenerative diseases that would enhance cellular ability to actively enclose harmful aggregates within protective inclusions, thereby neutralizing the toxic proteins.

Related Links:
Hebrew University of Jerusalem



New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.